Sector: Healthcare
findl.com provides a comprehensive suite of standardized financial statement data and an assortment of calculated metrics sourced directly from SEC filings, and meticulously cleansed and verified, ensuring reliability. To get the complete financial statement history in quarterly and annual resolution for PODD, sign up here.
Income Statement
Revenue
$1.7bn
Gross Profit
$1.2bn
Earning before Tax
$214.6m
Net Income
$206.3m
Net Income Common Shareholders
$206.3m
EPS
2.96
Balance Sheet
Cash
$704.2m
Debt
$1.4bn
Assets
$2.6bn
Liabilities
$1.9bn
Equity
$732.7m
Enterprise Value
$15.9bn
Cash Flow Statement
Net Cash from Operations
$145.7m
Net Cash from Investing
$-0.1bn
Net Cash from Financing
$-13.6m
Net Cash Flow
$14.5m
Free Cash Flow
$36.5m
Free Cash Flow per Share
$0.52
Metrics
Price to Equity
73.44
Price to Equity (Damodaran)
73.30
Price to Book
20.68
Net Margin
0.12
Return on Equity
0.34
Return on Sales
0.15
Get immediate access to 5-years of reference grade data for PODD for free.
Sign upInsulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Company Info
Industry
Medical Devices
Employees
2,600
Address
100 Nagog Park
Acton, MA 01720
United States
Phone
978 600 7000
Website
Last Updated
2024-02-15
Available Data
Standardized Financial Statements
EOD Price History
Corporate Actions
Institutional Holdings
Insider Transactions
Copyright © findl 2024. All rights reserved.